Radiation and medicine for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies a “salvage” (next-line) cancer treatment for recurrent epithelial ovarian cancer, with or without a focused type of radiation. It may help by shrinking or controlling limited spots of cancer that have come back after prior standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epithelial ovarian cancer that has been confirmed by pathology (lab testing).
- You finished your usual first treatment for your original tumor (surgery and chemotherapy if applicable).
- The recurrence is limited: you have 10 or fewer metastasis spots that doctors can map for radiation, and each spot is 5 cm or smaller.
- You are at least 19 years old and can do normal daily activities at a moderate level (Zubrod score 0–2).
- Your blood counts are strong enough: white cells (ANC) ≥ 500, platelets ≥ 50,000, and hemoglobin ≥ 8.0 (transfusions are allowed).
- You can give informed consent, and you have no brain metastases or certain fluid-based cancer spread.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
This trial tests a new approach using your own immune cells (tumor-infiltrating lymphocytes) that have been modified to work better, followed by a combination of oral chemo and immunotherapy. It's for people with ovarian cancer that has come back after standard treatment.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial studies whether a targeted treatment, chosen based on tumor biology, can help people with recurrent ovarian cancer. You may be asked to give a tumor biopsy so researchers can analyze specific “signal” activity in your cancer.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
Hear when a new Recurrent Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.